Abstract
We reported that HER2/neu reduces the sensitivity of breast cancer cells to N-(4-hydroxyphenyl)retinamide (4-HPR) by suppressing nitric oxide production. We show that HER2/neu uses Akt to induce cyclooxygenase-2 (COX-2) expression and that inhibition of Akt or COX-2 increases 4-HPR-induced apoptosis and nitric oxide production. Apoptosis induced by the 4-HPR and COX-2 inhibitor combination, although unaffected by an anti-HER2/neu antibody, was reversed by the COX-2 product prostaglandin E(2), indicating that COX-2 is a major mechanism by which HER2/neu suppresses 4-HPR apoptosis in breast cancer cells. Combining 4-HPR with COX-2 inhibitors may be a novel chemopreventive strategy against HER2/neu-overexpressing breast tumors.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Antineoplastic Agents / pharmacology*
-
Apoptosis / drug effects*
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / enzymology
-
Breast Neoplasms / pathology
-
Cell Line, Tumor
-
Cyclooxygenase 2
-
Cyclooxygenase 2 Inhibitors
-
Cyclooxygenase Inhibitors / pharmacology
-
Dinoprost / pharmacology
-
Female
-
Fenretinide / pharmacology*
-
Humans
-
Isoenzymes / physiology*
-
Membrane Proteins
-
Nitric Oxide / biosynthesis
-
Nitrobenzenes / pharmacology
-
Prostaglandin-Endoperoxide Synthases / physiology*
-
Protein Serine-Threonine Kinases*
-
Proto-Oncogene Proteins / antagonists & inhibitors
-
Proto-Oncogene Proteins c-akt
-
Receptor, ErbB-2 / physiology*
-
Sulfonamides / pharmacology
Substances
-
Antineoplastic Agents
-
Cyclooxygenase 2 Inhibitors
-
Cyclooxygenase Inhibitors
-
Isoenzymes
-
Membrane Proteins
-
Nitrobenzenes
-
Proto-Oncogene Proteins
-
Sulfonamides
-
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide
-
Fenretinide
-
Nitric Oxide
-
Dinoprost
-
Cyclooxygenase 2
-
PTGS2 protein, human
-
Prostaglandin-Endoperoxide Synthases
-
Receptor, ErbB-2
-
AKT1 protein, human
-
Protein Serine-Threonine Kinases
-
Proto-Oncogene Proteins c-akt